Discovery of a Selective pan-FGFR Inhibitor Approved for Treatment of Cholangiocarcinoma (Synfacts, 2023)
Keywords: futibatinib; pan-FGFR inhibitor; covalent drug; cholangiocarcinoma; hit-to-lead